The Blagg lab

Members of the Blagg Research Team are responsible for the design, synthesis, and evaluation of small molecules that modulate the Hsp90 protein folding process.  To achieve these goals, new molecules are designed using modern medicinal techniques that include computer modeling, high throughput screening, and/or crystal structures.  We also develop new organic reactions that allow access to the desired compounds in a highly efficient manner and develop assays that are suitable for determining the biological effects manifested by our rationally designed Hsp90 inhibitors.  We are currently engaged in more than 50 collaborative studies with researchers throughout the world!  The Blagg lab is comprised of organic chemists, biochemists, and biologists that are pursuing cutting edge interdisciplinary research.    

At present, we have produced one drug that is currently in Phase II clinical trials for neuropathy.  However, we also have advanced preclinical candidates for the treatment of cancer, Alzheimer's disease, and glaucoma.